- $26.87bn
- $28.00bn
- $163.07bn
- 80
- 94
- 70
- 96
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.17 | ||
| PEG Ratio (f) | 0.9 | ||
| EPS Growth (f) | 8.67% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.96 | ||
| Price to Tang. Book | 5.25 | ||
| Price to Free Cashflow | 18.01 | ||
| Price to Sales | 0.16 | ||
| EV to EBITDA | 5.77 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.22% | ||
| Return on Equity | 12.59% | ||
| Operating Margin | 2.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 111,115 | 125,982 | 144,547 | 153,999 | 163,071 | 180,437.73 | 181,303.66 | 16.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +22.9 | +5.43 | +18.49 | -9.6 | +4.43 | +7.61 | +9.7 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Centene Corporation is a healthcare company. The Company provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Its segments include Medicaid, Medicare, Commercial and Other. Specifically, the Medicaid segment includes the Temporary Assistance for Needy Families (TANF) program, Medicaid Expansion programs, the Aged, Blind or Disabled (ABD) program, the Children's Health Insurance Program (CHIP), Long-Term Services and Supports (LTSS), Foster Care, Medicare-Medicaid Plans (MMP), which cover beneficiaries who are dually eligible for Medicaid and Medicare and other state-based programs. The Medicare segment includes Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans and Medicare Prescription Drug Plans. The Commercial segment includes the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products.
Directors
- Michael Neidorff CHM (78)
- Brent Layton PRE (54)
- Sarah London VCH (41)
- Andrew Asher CFO (52)
- Shannon Bagley EVP
- Mark Brooks EVP (51)
- H. Robert Sanders EVP
- Brandy Burkhalter EVP (48)
- Colin Toney EVP
- Suzy DePrizio SVP
- Katie Casso SVP
- Rich Fisher SVP
- Jim Murray OTH
- Christopher Koster SEC (56)
- H. James Dallas LED (62)
- Orlando Ayala IND (64)
- Jessica Blume IND (66)
- Robert Ditmore IND (87)
- Frederick Eppinger IND (62)
- Richard Gephardt IND (80)
- Leslie Norwalk IND (55)
- John Roberts IND (79)
- Lori Robinson IND (62)
- Thomas Thompson IND (79)
- William Trubeck IND (74)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 26th, 2001
- Public Since
- December 13th, 2001
- No. of Shareholders
- 980
- No. of Employees
- 60,500
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 497,603,000
- Address
- 7700 Forsyth Blvd, ST. LOUIS, 63105-1807
- Web
- https://www.centene.com/
- Phone
- +1 3147254477
- Auditors
- KPMG LLP
Latest News for CNC
Upcoming Events for CNC
Q2 2025 Centene Corp Earnings Release
Q2 2025 Centene Corp Earnings Call
Q3 2025 Centene Corp Earnings Release
Similar to CNC
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ardent Health
New York Stock Exchange
Auna SA
New York Stock Exchange
FAQ
As of Today at 19:50 UTC, shares in Centene are trading at $53.99. This share price information is delayed by 15 minutes.
Shares in Centene last closed at $53.99 and the price had moved by -19.86% over the past 365 days. In terms of relative price strength the Centene share price has underperformed the S&P500 Index by -29.11% over the past year.
The overall consensus recommendation for Centene is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCentene does not currently pay a dividend.
Centene does not currently pay a dividend.
Centene does not currently pay a dividend.
To buy shares in Centene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $53.99, shares in Centene had a market capitalisation of $26.87bn.
Here are the trading details for Centene:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CNC
Based on an overall assessment of its quality, value and momentum Centene is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Centene is $75.79. That is 40.38% above the last closing price of $53.99.
Analysts covering Centene currently have a consensus Earnings Per Share (EPS) forecast of $7.19 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Centene. Over the past six months, its share price has underperformed the S&P500 Index by -14.75%.
As of the last closing price of $53.99, shares in Centene were trading -12.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Centene PE ratio based on its reported earnings over the past 12 months is 7.17. The shares last closed at $53.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Centene's management team is headed by:
- Michael Neidorff - CHM
- Brent Layton - PRE
- Sarah London - VCH
- Andrew Asher - CFO
- Shannon Bagley - EVP
- Mark Brooks - EVP
- H. Robert Sanders - EVP
- Brandy Burkhalter - EVP
- Colin Toney - EVP
- Suzy DePrizio - SVP
- Katie Casso - SVP
- Rich Fisher - SVP
- Jim Murray - OTH
- Christopher Koster - SEC
- H. James Dallas - LED
- Orlando Ayala - IND
- Jessica Blume - IND
- Robert Ditmore - IND
- Frederick Eppinger - IND
- Richard Gephardt - IND
- Leslie Norwalk - IND
- John Roberts - IND
- Lori Robinson - IND
- Thomas Thompson - IND
- William Trubeck - IND